Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

  • "Time to Disease-Related Pain After Sipuleucel-T in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Results from 3 Randomized Phase 3 Trials," abstract #4661. McCormick Place Hall A (Poster 12E) from 8:00 a.m. to 12:00 p.m. CT on Sunday, June 5, 2011.
  • "Quality of Life Assessment in Randomized, Double-Blind Study of Sipuleucel-T in Men with Androgen Dependent Prostate Cancer," abstract #4648. McCormick Place Hall A (Poster 10H) from 8:00 a.m. to 12:00 p.m. CT on Sunday, June 5, 2011.
  • "Post-Progression Treatment with APC8015F May Have Prolonged Survival of Subjects in the Control Arm of Sipuleucel-T Phase 3 Studies," abstract #4534. E450A from 2:00 to 6:00 p.m. CT on Saturday, June 4, 2011.
  • "Sipuleucel-T in African Americans: a Subgroup Analysis of Three Phase 3 Sipuleucel-T Trials in Advanced Prostate Cancer," abstract #E15148. Publication only.

PROVENGE was approved by the U.S. Food and Drug Administration (FDA) in April 2010 as the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

"In addition to the significant survival benefit PROVENGE has demonstrated in Phase 3 clinical trials, the data analyses presented at the 2011 ASCO annual meeting provide further insight into the immunotherapy's potential impact on patient sub-groups, as well as clinically important factors like time to disease-related pain and quality of life," said Mark Frohlich, M.D., executive vice president of research and development and chief medical officer of Dendreon.  "The data analyses in patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer continue to support the use of PROVENGE as a foundation of care in this patient population."

PROVENGE Indication and Safety

PROVENGE is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call Dendreon ON Call at 1-877-336-3736

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Morgan Stanley 15 ... Hyatt hotel in New York.  Zimmer Biomet will present ... Time. A live webcast of the presentation ... at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s PrevanticsĀ® Device Swab as ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... their latest industry white paper, entitled Barriers to Adoption of the ERA and ...
(Date:9/19/2017)... ... September 19, 2017 , ... Big ... recognized for its September 2016 donation of dog beds to the K9 officers ... awards and honors for its contribution from city and state officials. , ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Driving Dynamics Inc., ... Training Company by Training Industry Inc. as part of its mission to continually monitor ... Selection to the first annual 2017 Top 20 Health and Safety Training Companies list ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... annual PAINWeek National Conference. On October 7, at the Hilton Providence, 21 Atwells ... program providing busy clinicians and allied healthcare practitioners with 6.0 hours of relevant, ...
(Date:9/19/2017)... Boca Raton (PRWEB) , ... September 19, 2017 ... ... under the El Naturalista brand, developed by ACPG Laboratories, is coming soon to ... years in Spain, and El Naturalista is a trusted, well-respected brand reliant on ...
Breaking Medicine News(10 mins):